Dabigatran

"Dabigatran" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Descriptor ID	D000069604
MeSH Number(s)	D03.383.725.192 D03.633.100.103.280
Concept/Terms	Dabigatran Dabigatran N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine BIBR 1048 BIBR 1048 Pradaxa Pradaxa Dabigatran Etexilate Dabigatran Etexilate Etexilate, Dabigatran Dabigatran Etexilate Mesylate Dabigatran Etexilate Mesylate Etexilate Mesylate, Dabigatran Mesylate, Dabigatran Etexilate

Below are MeSH descriptors whose meaning is more general than "Dabigatran".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyridines [D03.383.725]
Dabigatran [D03.383.725.192]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Benzimidazoles [D03.633.100.103]
Dabigatran [D03.633.100.103.280]

Below are MeSH descriptors whose meaning is related to "Dabigatran".

Below are MeSH descriptors whose meaning is more specific than "Dabigatran".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dabigatran" by people in this website by year, and whether "Dabigatran" was a major or minor topic of these publications.

Bar chart showing 11 publications over 7 distinct years, with a maximum of 3 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	0	1	1
2011	0	3	3
2013	0	2	2
2014	0	2	2
2016	1	0	1
2018	0	1	1
2019	0	1	1

Below are the most recent publications written about "Dabigatran" by people in Profiles.

Takeshita S, Tanaka KA, Sawa T, Sanda M, Mizobe T, Ogawa S. Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran. Anesth Analg. 2020 02; 130(2):535-541.

View in: PubMed
Boylan PM, Santibañez M. Upper Gastrointestinal Bleeding in a Male Patient Taking Megestrol Acetate and Rivaroxaban: A Case Report. Sr Care Pharm. 2019 Sep 01; 34(8):501-509.

View in: PubMed
De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, Raskob GE, Siegal DM, Verheugt FWA, Lip GYH, Weitz JI. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38.

View in: PubMed
Desai RJ, Wyss R, Jin Y, Bohn J, Toh S, Cosgrove A, Kennedy A, Kim J, Kim C, Ouellet-Hellstrom R, Karami S, Major JM, Niman A, Wang SV, Gagne JJ. Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation. Am J Epidemiol. 2018 11 01; 187(11):2439-2448.

View in: PubMed
Najafzadeh M, Schneeweiss S, Choudhry NK, Wang SV, Gagne JJ. Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations. Clin Pharmacol Ther. 2018 11; 104(5):1008-1015.

View in: PubMed
Wang SV, Huybrechts KF, Fischer MA, Franklin JM, Glynn RJ, Schneeweiss S, Gagne JJ. Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2018 04; 27(4):383-390.

View in: PubMed
Ageno W, Casella IB, Han CK, Raskob GE, Schellong S, Schulman S, Singer DE, Kimura K, Tang W, Desch M, Goldhaber SZ. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost. 2017 01 26; 117(2):415-421.

View in: PubMed
Wang SV, Franklin JM, Glynn RJ, Schneeweiss S, Eddings W, Gagne JJ. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016 May 24; 353:i2607.

View in: PubMed
Henderson RS, Deshpande S, Williams B, Taylor BS, Tanaka KA. Idarucizumab for Dabigatran Reversal in Emergency Type-A Aortic Dissection. J Cardiothorac Vasc Anesth. 2017 12; 31(6):e80-e81.

View in: PubMed
Baber U, Mastoris I, Mehran R. Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nat Rev Cardiol. 2014 Dec; 11(12):693-703.

View in: PubMed

People

Explore

Similar Concepts

Top Journals